Truist Cuts Price Targets on Boston Scientific and Ameren, Keeps Buy Ratings
Truist Securities lowered its Boston Scientific target to $51 from $57 and Ameren's to $116 from $120, maintaining Buy ratings on both stocks, per Benzinga.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Truist Securities cut its price target on Boston Scientific (BSX) to $51.00 per share from $57.00 while keeping its Buy rating on the stock. Benzinga reported the change at 17:38 GMT on October 14, 2026.
Truist also lowered its target on Ameren (AEE) to $116.00 per share from $120.00 and maintained its Buy rating. Benzinga recorded this revision at 17:34 GMT the same day.
why it matters
A lower target alongside an unchanged Buy rating means the analyst revised its valuation estimate but did not change its positive stance. Single-broker moves like these rarely set the market consensus on their own, so they are best read alongside sector trends and company earnings results.
tags
instruments
sources
- Boston Scientific Price Target Cut to $51.00/Share From $57.00 by Truist Securities — Newsmetry API, 14 October 2026 at 17:38 UTC
- Ameren Price Target Cut to $116.00/Share From $120.00 by Truist Securities — Newsmetry API, 14 October 2026 at 17:34 UTC
- Sempra Price Target Cut to $94.00/Share From $96.00 by Truist Securities — Newsmetry API, 14 October 2026 at 17:50 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗